Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $2.7 million.

  • Exagen's Gains from Investment Securities changed N/A to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 122067.8%. This contributed to the annual value of $490000.0 for FY2024, which is 2969.87% down from last year.
  • Exagen's Gains from Investment Securities amounted to $2.7 million in Q3 2025.
  • Exagen's Gains from Investment Securities' 5-year high stood at $2.7 million during Q3 2025, with a 5-year trough of $30000.0 in Q2 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was $184500.0 (2023), whereas its average is $411500.0.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 1720000.0% in 2021, then crashed by 9460.43% in 2022.
  • Exagen's Gains from Investment Securities (Quarter) stood at $171000.0 in 2021, then crashed by 81.29% to $32000.0 in 2022, then skyrocketed by 387.5% to $156000.0 in 2023, then fell by 28.85% to $111000.0 in 2024, then soared by 2305.41% to $2.7 million in 2025.
  • Its Gains from Investment Securities was $2.7 million in Q3 2025, compared to $438000.0 in Q2 2025 and $677000.0 in Q1 2025.